Nurulimab
Nurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) human monoclonal antibody. Nurulimab can be can be used in research of melanoma[1].
Product Specifications
CAS Number
[2168561-20-2]
Product Name Alternative
BCD-145
UNSPSC
12352203
Target
CTLA-4
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/nurulimab.html
Purity
95.00
Solubility
10 mM in DMSO
Smiles
[Nurulimab]
Molecular Weight
(143.78 kDa)
References & Citations
[1]International Nonproprietary Names for Pharmaceutical Substances (INN) . WHO Drug Information, Vol. 34, No. 1, 2020.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
133116-ML750 100 µL
SENP7 (Sentrin-specific Protease 7, SUMO-1-specific Protease 2, Sentrin/SUMO-specific Protease SENP7, KIAA1707, SSP2, SUSP2) (MaxLight 750) discontinued
Ask
View Details 
